INCY Stock Analysis — Incyte Corporation
Sector: Healthcare
AI Verdict
At 18.1x next year's earnings and negative forward growth, you're paying a fair price for a defensible drug franchise, but the numbers say the recent run is fragile unless the pipeline delivers.
Competitive Moat
Incyte specializes in small-molecule drugs for oncology and inflammation, with Jakafi (ruxolitinib) as its anchor product protected by strong patent coverage and entrenched clinical adoption. Its pipeline is defensible due to deep expertise in targeted therapies and established relationships with hematologists.
Summary
Incyte's stock is on watch after a 44.48% one-year return despite analysts projecting -13.1% EPS growth ahead.
Where It Stands
The stock is up 44.48% over the past year, trades at 18.1x next year's earnings versus a healthcare median of 22x, and its RSI of 41.4 signals cooling momentum.
Key Metrics
- RSI: 41.4 — Neutral
- Trailing P/E: 15.7x
- Forward P/E: 18.1x
- Earnings Growth: -0.1%
- Revenue Growth: +0.3%
- Market Cap: $25.0B
- 1-Year Return: 44.48%
- 52-Week High: $132.60
- 52-Week Low: $81.09
Analyst Consensus
17 Buy · 16 Hold · 0 Sell (33 analysts)
Bull Case
Trading at 18.1x forward earnings, Incyte is cheaper than the healthcare sector median 22x, with a 26.9% trailing revenue growth rate that suggests recent operational strength.
Bear Case
With forward EPS expected to drop -13.1% and a trailing P/E of 15.7x, any multiple contraction toward the sector median could erase much of the recent 44.48% gain.
Catalyst to Watch
Watch for clinical trial readouts or regulatory decisions on pipeline drugs, as positive data could reverse the -13.1% EPS growth outlook.